Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACP3 | P15309 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.36 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.36 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6449523 | 0.86 | ACP3 (0.39) | ACP3ALDH1A1POLBKMT2A | |
| SCHEMBL846120 | 0.71 | ALDH1A1 (0.48) | ALDH1A1POLBKMT2A | |
| SCHEMBL18782394 | 0.70 | ALDH1A1 (0.52) | ALDH1A1POLBKMT2AAKR1C3AKR1C2 | |
| SCHEMBL5798610 | 0.69 | PGK1 (0.55) | ALDH1A1KDM4EGAA | |
| SCHEMBL3817936 | 0.69 | ACP3 (0.63) | ACP3POLB | |
| SCHEMBL21616493 | 0.69 | L3MBTL1 (0.51) | ACP3ALDH1A1 | |
| SCHEMBL4720153 | 0.69 | ACP3 (0.39) | ACP3ALDH1A1KMT2A | |
| SCHEMBL4689967 | 0.69 | HMGCR (0.46) | ALDH1A1POLBKMT2AGAASMN1; SMN2 | |
| SCHEMBL916478 | 0.69 | UGT2B7 (0.49) | ACP3KMT2A | |
| SCHEMBL10138510 | 0.69 | ALDH1A1 (0.50) | ALDH1A1POLBKMT2AKDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10550095-B2 | Cancerous cell growth inhibiting compounds | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2020-02-04 | — | — | US | disclosed |
| US-20170342047-A1 | Cancerous Cell Growth Inhibiting Compounds | WISYS TECHNOLOGY FOUNDATION, INC. | 2017-11-30 | — | — | US | disclosed |
| US-8530512-B2 | Broad spectrum gram-positive antimicrobials and anthelmintics with efficacy against drug-resistant strains and Mycobacterium species | MONTE AARON P (US) | 2013-09-10 | — | — | US | disclosed |
| US-20110092578-A1 | Broad Spectrum Gram-Positive Antimicrobials and Anthelmintics with Efficacy Against Drug-Resistant Strains and Mycobacterium Species | MONTE AARON P | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170342047-A1 | Cancerous Cell Growth Inhibiting Compounds | TYR, MKI67, MC1R | ACP3 663/4885ALDH1A1 113/4885POLB 1721/4885 |
| US-10550095-B2 | Cancerous cell growth inhibiting compounds | TYR, MKI67, MC1R | ACP3 663/4885ALDH1A1 113/4885POLB 1721/4885 |
| US-20110092578-A1 | Broad Spectrum Gram-Positive Antimicrobials and Anthelmintics with Efficacy Against Drug-Resistant Strains and Mycobacterium Species | ABCC1, H1-3, H1-2 | ACP3 1528/4885ALDH1A1 990/4885POLB 2458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.